Work

Why Don’t We Have Proven Treatments for HFpEF?

Year: 2017

Type: editorial

Abstract: T he lack of effective treatments for heart failure with preserved ejection fraction represents a large and growing unmet need in cardiology today.A critical obstacle to therapeutic innovation in heart failure with preserved ejection fraction has been the absence of animal models that accurately recapitulate the complexities of the human disease.Here, we propose that more comprehensive multiorgan system and functional phenotyping of preclinical models is essential if we are to maximize our chances of discovering and validating novel targets for effective therapeutic development in heart failure with preserved ejection fraction.Why Don't We Have Proven Treatments for HFpEF?

Source: Circulation Research

DOI: 10.1161/circresaha.116.310119

Authors: Jason Roh, Nicholas Houstis, Anthony Rosenzweig

Institutions: Harvard University, Massachusetts General Hospital

Language: English

Topic: Cardiovascular Function and Risk Factors

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute, National Center for Advancing Translational Sciences